“…28 Some clinical data for patients NCL31, NCL32, and NCL35 have previously been published. 29 The incidence rates for complement-mediated aHUS and DGKE aHUS were calculated using the estimated population of England according to the Office for National Statistics. 30 The calculation of the incidence of complement-mediated aHUS included patients referred to the NRCTC with TMA in which the following conditions were excluded using genetic and serological analysis or on the basis of clinical context: thrombotic thrombocytopenic purpura, shiga toxin-producing E coli HUS, disseminated intravascular coagulation, pneumococcal HUS, HIV, drug-induced TMA, severe hypertensionassociated TMA, cobalamin C deficiency-associated TMA, malignant neoplasm-associated TMA, bone marrow transplantationassociated TMA, de novo TMA after solid organ transplantation, glomerular disease-associated TMA, and autoimmune diseaseassociated TMA.…”